Literature DB >> 31351319

Structural and binding insights into HIV-1 protease and P2-ligand interactions through molecular dynamics simulations, binding free energy and principal component analysis.

Konda Reddy Karnati1, Yixuan Wang2.   

Abstract

HIV-1 protease (HIV-1-pr) plays an important role in viral replication and maturation, making it one of the most attractive targets for anti-retroviral therapy. To design new effective inhibitors able to combat drug resistance in mutant HIV-1-pr variants, it is essential to gain further understanding about the mechanisms by which the recently proposed inhibitors deactivate the mutant HIV-1-pr variants. In the present work, we explored the interactions between two P2-ligands (DRV, and one new derivative, 4UY) with wild type (WT) and two multiple mutant HIV-1-pr variants (p20 and p51) with all atom molecular dynamics (MD) simulations, binding free energy calculations, and principal component analysis (PCA). The trajectories of MD simulations show that both 4UY and DRV primarily bind with the active sites, flap and 80s loop regions of HIV-1-pr variants through either hydrogen bonds or hydrophobic interactions. More hydrogen bonds and hydrophobic interactions were located for 4UY/HIV-1-pr complexes than for DRV/HIV-1-pr counterparts. More importantly, 4UY was found to have an extra hydrogen bond with the backbone of Gly48' in the flap region of the HIV-1-prs. The flap tip-tip distance (I50-I50') and flap tip-active site distance (I50-D25 and I50'-D25') indicate that the flaps turn more closed in 4UY bound HIV-1-prs than DRV bound ones, and the former also have more compact hydrophobic cavities than the latter. Further, the vector projections from PCA indicate that 4UY/DRV inhibitor binding projects the closing of flap in HIV-1-pr variants. In line with the above trajectory analysis, the thermodynamics calculation with MM-PBSA method suggests much stronger binding affinity for 4UY/HIV-1-pr than DRV/HIV-1-pr by 4.3-6.4 kcal/mol. Although p20 and p51 also induce weaker binding due to multiple mutants for 4UY inhibitor by 1.9-1.8 kcal/mol, their bindings to the new P2 ligand (4UY) are indeed significantly enhanced as compared to DRV. The thermodynamic components responsible for the binding differences and the contribution from key residues to the binding were also discussed in detail.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  4UY; Binding free energy; DRV; HIV-1-pr; Molecular dynamics simulation; principal component analysis

Mesh:

Substances:

Year:  2019        PMID: 31351319      PMCID: PMC6732013          DOI: 10.1016/j.jmgm.2019.07.008

Source DB:  PubMed          Journal:  J Mol Graph Model        ISSN: 1093-3263            Impact factor:   2.518


  37 in total

Review 1.  HIV-1 protease: mechanism and drug discovery.

Authors:  Ashraf Brik; Chi-Huey Wong
Journal:  Org Biomol Chem       Date:  2003-01-07       Impact factor: 3.876

2.  Development and testing of a general amber force field.

Authors:  Junmei Wang; Romain M Wolf; James W Caldwell; Peter A Kollman; David A Case
Journal:  J Comput Chem       Date:  2004-07-15       Impact factor: 3.376

3.  Molecular dynamics simulations applied to the study of subtypes of HIV-1 protease common to Brazil, Africa, and Asia.

Authors:  Paulo R Batista; Alan Wilter; Elza H A B Durham; Pedro G Pascutti
Journal:  Cell Biochem Biophys       Date:  2006       Impact factor: 2.194

4.  Ligand configurational entropy and protein binding.

Authors:  Chia-en A Chang; Wei Chen; Michael K Gilson
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-22       Impact factor: 11.205

5.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Authors:  Yuan-Fang Wang; Yunfeng Tie; Peter I Boross; Jozsef Tozser; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

6.  Curling of flap tips in HIV-1 protease as a mechanism for substrate entry and tolerance of drug resistance.

Authors:  W R Scott; C A Schiffer
Journal:  Structure       Date:  2000-12-15       Impact factor: 5.006

7.  Structural and thermodynamic basis for the binding of TMC114, a next-generation human immunodeficiency virus type 1 protease inhibitor.

Authors:  Nancy M King; Moses Prabu-Jeyabalan; Ellen A Nalivaika; Piet Wigerinck; Marie-Pierre de Béthune; Celia A Schiffer
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

8.  Effectiveness of nonpeptide clinical inhibitor TMC-114 on HIV-1 protease with highly drug resistant mutations D30N, I50V, and L90M.

Authors:  Andrey Yu Kovalevsky; Yunfeng Tie; Fengling Liu; Peter I Boross; Yuan-Fang Wang; Sofiya Leshchenko; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2006-02-23       Impact factor: 7.446

9.  High resolution crystal structures of HIV-1 protease with a potent non-peptide inhibitor (UIC-94017) active against multi-drug-resistant clinical strains.

Authors:  Yunfeng Tie; Peter I Boross; Yuan-Fang Wang; Laquasha Gaddis; Azhar K Hussain; Sofiya Leshchenko; Arun K Ghosh; John M Louis; Robert W Harrison; Irene T Weber
Journal:  J Mol Biol       Date:  2004-04-23       Impact factor: 5.469

Review 10.  Darunavir, a conceptually new HIV-1 protease inhibitor for the treatment of drug-resistant HIV.

Authors:  Arun K Ghosh; Zachary L Dawson; Hiroaki Mitsuya
Journal:  Bioorg Med Chem       Date:  2007-09-14       Impact factor: 3.641

View more
  4 in total

Review 1.  From Data to Knowledge: Systematic Review of Tools for Automatic Analysis of Molecular Dynamics Output.

Authors:  Hanna Baltrukevich; Sabina Podlewska
Journal:  Front Pharmacol       Date:  2022-03-10       Impact factor: 5.810

2.  Effective estimation of the inhibitor affinity of HIV-1 protease via a modified LIE approach.

Authors:  Son Tung Ngo; Nam Dao Hong; Le Huu Quynh Anh; Dinh Minh Hiep; Nguyen Thanh Tung
Journal:  RSC Adv       Date:  2020-02-21       Impact factor: 4.036

3.  Acquired HIV-1 Protease Conformational Flexibility Associated with Lopinavir Failure May Shape the Outcome of Darunavir Therapy after Antiretroviral Therapy Switch.

Authors:  Simeon Eche; Ajit Kumar; Nelson Sonela; Michelle L Gordon
Journal:  Biomolecules       Date:  2021-03-24

4.  Ritonavir and xk263 Binding-Unbinding with HIV-1 Protease: Pathways, Energy and Comparison.

Authors:  Jianan Sun; Mark Anthony V Raymundo; Chia-En A Chang
Journal:  Life (Basel)       Date:  2022-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.